Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors
Evoke Pharma (NASDAQ: EVOK) has appointed Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This is the second board member appointment by Nantahala Capital Management, showing their continued confidence in Evoke's strategy. Pyszczymuka, currently Chief Commercial Officer at Aytu BioPharma, brings extensive experience in pharmaceutical sales and market access.
Under his leadership at Aytu, the company achieved operational profitability and sustainable revenue growth. His 20-year career includes senior roles at Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. The appointment aims to strengthen Evoke's market presence and enhance shareholder value, particularly in expanding access to GIMOTI®, their metoclopramide nasal spray for gastrointestinal diseases.
Evoke Pharma (NASDAQ: EVOK) ha nominato Greg Pyszczymuka nel suo Consiglio di Amministrazione, con effetto dal 20 febbraio 2025. Questa è la seconda nomina di un membro del consiglio da parte di Nantahala Capital Management, a dimostrazione della loro continua fiducia nella strategia di Evoke. Pyszczymuka, attualmente Chief Commercial Officer presso Aytu BioPharma, porta con sé una vasta esperienza nelle vendite farmaceutiche e nell'accesso al mercato.
Sotto la sua guida ad Aytu, l'azienda ha raggiunto la redditività operativa e una crescita sostenibile dei ricavi. La sua carriera di 20 anni include ruoli di alto livello presso Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix ed Endo Pharmaceuticals. La nomina mira a rafforzare la presenza di Evoke sul mercato e a migliorare il valore per gli azionisti, in particolare nell'espansione dell'accesso a GIMOTI®, il loro spray nasale di metoclopramide per le malattie gastrointestinali.
Evoke Pharma (NASDAQ: EVOK) ha nombrado a Greg Pyszczymuka en su Junta Directiva, con efecto a partir del 20 de febrero de 2025. Esta es la segunda designación de un miembro de la junta por parte de Nantahala Capital Management, lo que demuestra su continua confianza en la estrategia de Evoke. Pyszczymuka, actualmente Director Comercial en Aytu BioPharma, aporta una amplia experiencia en ventas farmacéuticas y acceso al mercado.
Bajo su liderazgo en Aytu, la empresa logró rentabilidad operativa y un crecimiento sostenible de ingresos. Su carrera de 20 años incluye roles senior en Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix y Endo Pharmaceuticals. La designación tiene como objetivo fortalecer la presencia de Evoke en el mercado y mejorar el valor para los accionistas, particularmente en la expansión del acceso a GIMOTI®, su spray nasal de metoclopramida para enfermedades gastrointestinales.
Evoke Pharma (NASDAQ: EVOK)는 2025년 2월 20일부터 Greg Pyszczymuka를 이사회의 이사로 임명했습니다. 이는 Nantahala Capital Management의 두 번째 이사 임명으로, Evoke의 전략에 대한 지속적인 신뢰를 보여줍니다. 현재 Aytu BioPharma의 최고 상업 책임자인 Pyszczymuka는 제약 판매 및 시장 접근에 대한 폭넓은 경험을 가지고 있습니다.
Aytu에서 그의 리더십 아래, 회사는 운영 수익성과 지속 가능한 수익 성장을 달성했습니다. 그의 20년 경력에는 Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix 및 Endo Pharmaceuticals에서의 고위직이 포함됩니다. 이번 임명은 Evoke의 시장 존재감을 강화하고 주주 가치를 높이는 것을 목표로 하며, 특히 GIMOTI®의 접근성을 확대하는 데 중점을 두고 있습니다. 이는 위장 질환을 위한 메토클로프라미드 비강 스프레이입니다.
Evoke Pharma (NASDAQ: EVOK) a nommé Greg Pyszczymuka au sein de son Conseil d'Administration, à compter du 20 février 2025. Il s'agit de la deuxième nomination d'un membre du conseil par Nantahala Capital Management, témoignant de leur confiance continue dans la stratégie d'Evoke. Pyszczymuka, actuellement Directeur Commercial chez Aytu BioPharma, apporte une vaste expérience dans les ventes pharmaceutiques et l'accès au marché.
Sous sa direction chez Aytu, l'entreprise a atteint la rentabilité opérationnelle et une croissance durable des revenus. Sa carrière de 20 ans comprend des postes de direction chez Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix et Endo Pharmaceuticals. Cette nomination vise à renforcer la présence d'Evoke sur le marché et à améliorer la valeur pour les actionnaires, en particulier en élargissant l'accès à GIMOTI®, leur spray nasal de métoclopramide pour les maladies gastro-intestinales.
Evoke Pharma (NASDAQ: EVOK) hat Greg Pyszczymuka in seinen Vorstand berufen, mit Wirkung zum 20. Februar 2025. Dies ist die zweite Ernennung eines Vorstandsmitglieds durch Nantahala Capital Management, was ihr fortgesetztes Vertrauen in die Strategie von Evoke zeigt. Pyszczymuka, der derzeit Chief Commercial Officer bei Aytu BioPharma ist, bringt umfangreiche Erfahrungen im Bereich pharmazeutischer Verkäufe und Marktzugang mit.
Unter seiner Leitung erzielte Aytu operative Rentabilität und nachhaltiges Umsatzwachstum. Seine 20-jährige Karriere umfasst Führungspositionen bei Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix und Endo Pharmaceuticals. Die Ernennung zielt darauf ab, die Marktpräsenz von Evoke zu stärken und den Shareholder-Wert zu erhöhen, insbesondere durch die Erweiterung des Zugangs zu GIMOTI®, ihrem Nasenspray mit Metoclopramid für gastrointestinale Erkrankungen.
- Appointment strengthens commercial expertise with proven leader in pharmaceutical sales and market access
- Second board appointment by major investor Nantahala Capital Management shows continued confidence
- New director has track record of achieving operational profitability and revenue growth at Aytu BioPharma
- None.
SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke’s commercial strategy and growth potential.
Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commercial Officer at Aytu BioPharma, a Nasdaq-listed company specializing in the commercialization of prescription products, where he has played a pivotal role in driving the company to operational profitability. Under his leadership, Aytu has strengthened its financial performance and achieved sustainable revenue growth over the past two years. His expertise in expanding prescription product revenues and optimizing commercial operations has contributed to Aytu’s continued financial momentum.
“We are excited to welcome Greg to our Board of Directors,” said Matt D'Onofrio, CEO of Evoke Pharma. “His deep expertise in commercial strategy and revenue optimization, coupled with his success in driving robust financial performance, aligns perfectly with Evoke’s ongoing growth trajectory. As we continue expanding access to Gimoti®, Greg’s insights will be instrumental in helping us strengthen our market presence and enhance shareholder value.”
Prior to Aytu, he held senior commercial leadership roles at Neos Therapeutics, including Vice President, Commercial Strategy & Market Access, and Vice President, Commercial. Over his 20-year career, he has built and led high-performing teams across sales, brand management, managed markets, and business development. His career also includes leadership positions at Aqua Pharmaceuticals (an Almirall company), Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.
Mr. Pyszczymuka commented, “I am honored to join Evoke’s Board of Directors at this exciting time. Evoke’s commitment to addressing the needs of patients with diabetic gastroparesis resonates deeply with me, and I look forward to leveraging my experience to help drive commercial success. With Gimoti® gaining market traction, I see tremendous opportunities to further expand adoption and accelerate growth.”
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, the potential market opportunity for GIMOTI, Evoke’s partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
FAQ
When did Greg Pyszczymuka join EVOK's Board of Directors?
What is Greg Pyszczymuka's current role outside of EVOK?
How many board members has Nantahala Capital Management appointed to EVOK?
What is EVOK's main product focus?
What experience does Greg Pyszczymuka bring to EVOK's board?
